UK markets closed

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
40.90+0.08 (+0.18%)
At close: 5:35PM CEST
Full screen
Previous close40.83
Open41.03
Bid40.88 x N/A
Ask40.88 x N/A
Day's range40.81 - 41.34
52-week range31.03 - 47.60
Volume2,642,741
Avg. volume943,813
Market cap27.11B
Beta (5Y monthly)1.28
PE ratio (TTM)13.11
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.88 (2.15%)
Ex-dividend date25 May 2021
1y target estN/A
All
News
  • EQS Group

    Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

    Fresenius SE & Co. KGaA / Key word(s): ForecastFresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/2101-Feb-2021 / 22:49 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21Current Group expectations for FY/21Based on the current status of the Group's financial planning process and assuming that the current burdens and constraints caused by the COVID-19 pandemic only begin to recede in the second half of the year, Fresenius targets healthy sales growth1 and at least broadly stable net income2 year over year in FY/21. The FY/21 earnings are, hence, expected to be very meaningfully impacted by COVID-19 effects. In particular, as reported today by Fresenius Medical Care, the significant acceleration of mortality among dialysis patients due to COVID-19 is expected to have a material impact on Fresenius Medical Care's results and hence on Fresenius Group's net income2 growth.Group medium-term targetsThe current information and assumptions do not trigger a revision of Fresenius' medium-term growth targets, which were set before the COVID-19 pandemic emerged.Fresenius will announce more detailed FY/21 financial guidance with the release of its FY/20 results on February 23, 2021.1 in constant currency2 Net income attributable to shareholders of Fresenius SE & Co. KGaA; in constant currency; before any special items and any one-time expenses related to likely efficiency and cost saving programsFor additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.Fresenius SE & Co. KGaA,represented by Fresenius Management SE,The Management BoardBad Homburg v.d.H., February 1, 2021----------------------------------------Contact:Markus GeorgiSenior Vice President Investor Relations & SustainabilityT: +49 (0) 6172 608-2485markus.georgi@fresenius.com----------------------------------------End of Note01-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: ir-fre@fresenius.com Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange EQS News ID: 1164992 End of Announcement DGAP News Service